Ex Vivo Drug Response Profiling and Outcome Prediction in Lung Adenocarcinoma
NCT07636252 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400
Last updated 2026-06-23
Summary
This observational study evaluates if ex-vivo lung cancer drug sensitivity testing results correlate with the driver mutations found by genetic sequencing and if it can predict treatment response.
Conditions
- Lung Adenocarcinoma
- Malignant Pleural Effusions (Mpe)
Interventions
- OTHER
-
Non-Interventional Study
Non-Interventional Study, patients go through pleural drainage due to shortness of breath
Sponsors & Collaborators
-
Sheba Medical Center
lead OTHER_GOV
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-06-14
- Primary Completion
- 2028-12-01
- Completion
- 2030-01-01
Countries
- Israel
Study Locations
More Related Trials
-
Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy
NCT04676386 ·Status: TERMINATED
-
Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer
NCT00702962 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura
NCT00019825 ·Status: COMPLETED ·Phase: PHASE1
-
Etirinotecan Pegol (NKTR-102) in NSCLC
NCT01773109 ·Status: COMPLETED ·Phase: PHASE2
-
Patient-derived Tumor-like Cell Cluster Model-based Precision Treatment Strategy on Non-small Cell Lung Cancer
NCT07328945 ·Status: RECRUITING
-
Identification by Microarrays of the Risks of Metastatic Relapse, Toxicity and Resistance to Adjuvant Chemotherapy in Completely Resected Non-small Cell Lung Cancer
NCT02075957 ·Status: UNKNOWN
-
Exploratory Study of QBKPN SSI in Non-Small Cell Lung Cancer
NCT02256852 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT06624059 ·Status: COMPLETED ·Phase: PHASE3
-
Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
NCT04367311 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
NCT07250477 ·Status: RECRUITING ·Phase: PHASE2
-
Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma
NCT02668393 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacogenomic Study Realized on "Non-small Cell Lung Carcinoma"
NCT00222404 ·Status: COMPLETED
-
A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma
NCT01439568 ·Status: COMPLETED ·Phase: PHASE2
-
A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC
NCT04807114 ·Status: RECRUITING
-
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT04619797 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
NCT04297605 ·Status: RECRUITING ·Phase: PHASE1
-
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
NCT04656652 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer
NCT01233687 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label
NCT02318368 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC
NCT06328049 ·Status: RECRUITING ·Phase: PHASE2
-
Maintenance Therapy for Small-cell Lung Cancer
NCT03769935 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy
NCT01328951 ·Status: COMPLETED ·Phase: PHASE3
-
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
NCT07489066 ·Status: RECRUITING ·Phase: PHASE2
-
NovellusDx Functional Profiling of Oncogenic Mutations in Lung Cancer Patients
NCT02274025 ·Status: COMPLETED
-
Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer
NCT00989690 ·Status: UNKNOWN ·Phase: PHASE3